1441309-05-2

Upstream product

• 20829-96-3 5-chloro-1H-benzo[d][1,3]oxazine-2,4-dione 
• 62-53-3 aniline 
• 2148-56-3 2-chloro-6-aminobenzoic acid 
• 15761-38-3 L-N-Boc-Ala 
• 50460-70-3 2-amino-6-chloro-N-phenylbenzamide 

Downstream Products

• 1420627-35-5 (S)-2-(1-aminoethyl)-5-chloro-3-phenylquinazoline-4(3H)-one 
• 1441309-09-6 tert-butyl (S)-(1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazoline-2-yl)ethyl)carbamate 
• 1448894-89-0 (S)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)-ethyl)amino)pyrimidine-5-carbonitrile 
• 1441309-01-8 C₂₆H₂₄ClN₇O₂ 
• 1441308-78-6 (S)-5-chloro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)ethyl]quinazolin-4(3H)-one 

Relevant academic research and scientific papers

Substituted aminopyrimidine compounds and their method and use thereof

The invention relates to a new aminopyrimidine compound and an application thereof as a drug for treating disorder or diseases related to PI3-kinase abnormity in a free form or a pharmaceutically acceptable salt and preparation form. The invention also relates to a pharmaceutical composition which contains the new aminopyrimidine compound and an application of the pharmaceutical composition in treating mammal disorder or diseases and especially treating human disorder or diseases related to the PI3-kinase abnormity, such as treatment of immunity and inflammatory diseases of PI3-kinase regulation which plays a leading role in a leucocyte function and treatment of proliferative diseases which are related to PI3-kinase activity and include but not limited to leukaemia and solid tumor.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase a

PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS PI3K INHIBITORS

Compounds (I) and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

COMPOSITIONS AND METHODS OF TREATING A DISEASE WITH (S)-4 AMINO-6-((1-(5-CHLORO-4-OXO-3-PHENYL-3,4-DIHYDROQUINAZOLIN-2-YL)ETHYL)AMINO)PYRIMIDINE-5-CARBONITRILE

Provided are methods that relate to a novel therapeutic strategy for the treatment of asthma. In particular, the method comprises administration of Compound A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.

COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE

Provided are methods that relate to a novel therapeutic strategy for the treatment of cancers. In particular, the method comprises administration of Compound A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.